Lineage Cell Therapeutics (LCTX) Construction in Progress (2014 - 2019)

Lineage Cell Therapeutics' Construction in Progress history runs 6 years deep, the most recent figure standing at $8.9 million for Q1 2019.

• In Q1 2019, Construction in Progress changed N/A year-over-year to $8.9 million; the TTM figure through Mar 2019 stood at $8.9 million (changed N/A YoY), while the FY2018 annual figure was $1.3 million, down 77.08% from the prior year.
• Construction in Progress for Q1 2019 stood at $8.9 million, up from $1.3 million in the prior quarter.
• The five-year high for Construction in Progress was $8.9 million in Q1 2019, with the low at $93000.0 in Q4 2015.
• The 5-year median for Construction in Progress is $1.6 million (2016), against an average of $3.1 million.
• The sharpest annual moves came in 2015 and 2016: Construction in Progress plunged 77.09% in 2015, then surged 117.26% in 2016.
• Lineage Cell Therapeutics' Construction in Progress stood at $93000.0 in 2015, then surged by 1620.43% to $1.6 million in 2016, then jumped by 245.81% to $5.5 million in 2017, then plunged by 77.08% to $1.3 million in 2018, then soared by 603.31% to $8.9 million in 2019.
• Business Quant data shows LCTX's Construction in Progress at $8.9 million in Q1 2019, $1.3 million in Q4 2018, and $5.1 million in Q3 2018.